Global Dysmenorrhea Treatment Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de tratamento da dismenorreia

O mercado de tratamento da dismenorreia está a expandir-se como resultado de dois factores-chave primários, tais como a crescente consciencialização dos consumidores sobre a terapêutica da dismenorreia e o baixo preço dos medicamentos vendidos sem receita médica. De acordo com o artigo publicado na Women’s Health Concern e na British Menopause Society em dezembro de 2020, cerca de 80% das mulheres com dismenorreia apresentam dores menstruais em algum momento da vida. O lançamento de vários novos produtos para o tratamento da dor relacionada com a dismenorreia primária e secundária está também a impulsionar o mercado.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado de tratamento da dismenorreia no período de previsão 2023-2030. O CAGR esperado do mercado de tratamento da dismenorreia tende a rondar os 8,8% no período de previsão mencionado. O mercado foi avaliado em 5.937,8 milhões de dólares em 2022 e cresceria até 11.658,88 milhões de dólares até 2030. Para além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de tratamento da dismenorreia

Definição de mercado

A dismenorreia é um tipo de condição caracterizada por períodos dolorosos e cólicas menstruais. A condição ocorre com dor insuportável durante a menstruação nas mulheres. Os sintomas duram geralmente menos de três dias; a dor ocorre geralmente na pélvis ou na parte inferior do abdómen. A dor ocorre geralmente 1 ou 2 dias antes do início do sangramento menstrual e é geralmente sentida na zona inferior do abdómen, coxas e costas. A gravidade da dor pode variar e também pode durar entre 12 a 72 horas. Os sintomas mais comuns da dismenorreia são a fadiga, a diarreia e as alterações de humor.

Dinâmica global do mercado de tratamento da dismenorreia

Motoristas

• Aumento dos sintomas de dor menstrual

De acordo com o artigo publicado na Women’s Health Concern e na British Menopause Society em dezembro de 2020, cerca de 80% das mulheres com dismenorreia apresentam dores menstruais em algum momento da vida. Em cerca de 40% das mulheres, a dor menstrual é acompanhada por sintomas pré-menstruais, como inchaço, estômago inchado, seios sensíveis, falta de concentração, alterações de humor, falta de jeito e cansaço. Isto impulsiona o crescimento do mercado.

• Crescentes estudos de investigação sobre a doença

De acordo com o estudo intitulado "Combinação de dose fixa de AINEs e agentes espasmolíticos no tratamento de diferentes tipos de dor - uma revisão prática", publicado em julho de 2021, muitas combinações de anti-inflamatórios não esteróides (AINEs) e espasmolíticos têm sido desenvolvidas e testados, indicando um enorme potencial para futuras pesquisas no desenvolvimento de combinações modernas e eficazes e na procura de novas indicações para os medicamentos combinados de dose fixa existentes para o tratamento da dismenorreia.

Oportunidades

• Aumento do lançamento de novos produtos

O lançamento de inúmeros novos produtos para o tratamento da dor relacionada com a dismenorreia primária e secundária está também a impulsionar o mercado estudado. Por exemplo, em setembro de 2021, a Myovant Sciences e a Pfizer Inc. receberam a aprovação da FDA dos EUA para a revisão de um pedido suplementar de novo medicamento (sNDA) para o MYFEMBREE (relugolix 40 mg, estradiol 1 mg e acetato de noretindrona 0, 5 mg) para gerir a dor moderada a intensa associada à endometriose. Assim, estes diversos lançamentos criam muitas oportunidades de mercado.

• Crescentes lançamentos de startups para a saúde reprodutiva

Several start-ups have been launched by various organizations, leading to market growth. For instance, Gynica is a FemTech startup based in Israel. It is mainly responsible for the manufacturing of cannabis-based treatments for women's reproductive health. Gynica is a medical firm which is focused on studying and developing marijuana treatments for several gynecological disorders and symptoms. They are members of Station F's FemTech Cohort. This creates more opportunity in the market.

Restraints/Challenges

The high cost of care will hinder the market's growth rate during the forecast period of 2022-2030. Lack of public awareness and inadequate reimbursement policies may impede and impede market expansion during the projection period of 2022-2030.

Moreover, challenges related with long-term care and other side effects and issues, the high morbidity of menstrual cramps because of insufficient treatments, and traditional family values are projected to decrease the growth of the dysmenorrhea treatment market.

This global dysmenorrhea treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dysmenorrhea treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Dysmenorrhea Treatment Market

COVID-19 has impacted the emotional and mental health of the people majorly. It has been witnessed that periods of stress and psychological distress can affect a woman’s menstrual health. The severe changes in menstrual cycles can lead to higher episodes of dysmenorrhea, considerably impacting the market. As per the study titled "The Impact of the COVID-19 Pandemic on Women’s Reproductive Health", published in March 2021, 46% of women reported a change in their menstrual cycle, with 30% new dysmenorrhea cases, since the beginning of the pandemic. Thus, COVID-19 has impacted the dysmenorrhea treatment market significantly.

Recent Development:

• In December 2020, Nua announced the release of a first-of-its-kind period pain relief solution called Cramps Comfort. Nua has released a revolutionary self-heating patch that can deliver up to 8 hours of heat to improve period discomfort.
• In 2022, Cora® debuted its fresh comfort-focused brand image, feel, and identity. Furthermore, company has expanded its range of products to fulfil the need of consumers.

Global Dysmenorrhea Treatment Market Scope

The global dysmenorrhea treatment market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary Dysmenorrhea
• Secondary Dysmenorrhea

Treatment

• Hormonal Therapy
• Pain Reliever
• Surgery
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Dysmenorrhea Treatment Market Regional Analysis/Insights

The dysmenorrhea treatment market is analyzed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.

The major countries covered in the dysmenorrhea treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key product manufacturers and increasing research and development activities.

Asia-Pacific dominates the market due to increased new research and developments on dysmenorrhea treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Dysmenorrhea Treatment Market Share Analysis

The dysmenorrhea treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dysmenorrhea treatment market.

Key players operating in the dysmenorrhea treatment market include:

• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Ipsen Pharma (France)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• Takeda Pharmaceutical Company Limited. (Japan)
• BeyondSpring Inc. (U.S.)
• Apotex Inc. (Canada)
• Taj Pharmaceuticals, Limited. (India)
• Sanofi (France)
• Terramedic Incorporated (Philippines)
• Nua (India)
• Cora (India)

SKU-56674